Clinical case of long-term use of osimertinib in the treatment of EGFR mutation-positive lung adenocarcinoma
This article reviews clinical case of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer and the usage of osimertinib for its treatment. Targeted drugs, EGFR tyrosine kinase inhibitors were approved for the treatment of non-small cell lung cancer more than 15 years...
Main Authors: | Svetlana V. Odintsova, Mariia A. Sviridenko, Antonina O. Cheremnykh, Elena A. Filippova, Magaripa A. Urtenova, Sergei V. Orlov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IP Habib O.N.
2020-07-01
|
Series: | Современная онкология |
Subjects: | |
Online Access: | https://modernonco.orscience.ru/1815-1434/article/viewFile/34962/23379 |
Similar Items
-
Osimertinib for compound EGFR exon 19 deletion/T790M mutated lung squamous cell carcinoma
by: MuYun Peng, et al.
Published: (2020-09-01) -
Osimertinib in EGFR-Mutated Lung Cancer: A Review of the Existing and Emerging Clinical Data
by: Lee CS, et al.
Published: (2021-08-01) -
Osimertinib-associated ashy dermatosis–like hyperpigmentation
by: Pattamon Lertpichitkul, MD, et al.
Published: (2020-02-01) -
Long‐term response to osimertinib in elderly patients with lung adenocarcinoma harbouring de novo EGFR T790M: a case report and literature review
by: Toshiyuki Sumi, et al.
Published: (2021-06-01) -
Final Overall Survival Results from the FLAURA Trial: a Phase III Study on Osimertinib in EGFRMutated Advanced Non-small Cell Lung Cancer
by: Yue WANG, et al.
Published: (2020-06-01)